Development of plant-produced protein body vaccine candidates for bluetongue virus

Simple item page
dc.contributor.authorvan Zyl, Albertha R
dc.contributor.authorMeyers, Ann E
dc.contributor.authorRybicki, Edward P
dc.date.accessioned2017-06-05T08:47:24Z
dc.date.available2017-06-05T08:47:24Z
dc.date.issued2017-05-30
dc.date.updated2017-06-04T03:38:10Z
dc.description.abstractBackground: Bluetongue is a disease of domestic and wild ruminants caused by bluetongue virus serotypes (BTV), which have caused serious outbreaks worldwide. Commercially available vaccines are live-attenuated or inactivated virus strains: these are effective, but there is the risk of reversion to virulence or reassortment with circulating strains for live virus, and residual live virus for the inactivated vaccines. The live-attenuated virus vaccines are not able to distinguish naturally infected animals from vaccinated animals (DIVA compliant). Recombinant vaccines are preferable to minimize the risks associated with these vaccines, and would also enable the development of candidate vaccines that are DIVA-compliant. Results: In this study, two novel protein body (PB) plant-produced vaccines were developed, Zera®-VP2ep and Zera®-VP2. Zera®-VP2ep contained B-cell epitope sequences of multiple BTV serotypes and Zera®-VP2 contained the full-length BTV-8 VP2 codon-optimised sequence. In addition to fulfilling the DIVA requirement, Zera®-VP2ep was aimed at being multivalent with the ability to stimulate an immune response to several BTV serotypes. Both these candidate vaccines were successfully made in N. benthamiana via transient Agrobacterium-mediated expression, and in situ TEM analysis showed that the expressed proteins accumulated within the cytoplasm of plant cells in dense membrane-defined PBs. The peptide sequences included in Zera®-VP2ep contained epitopes that bound antibodies produced against native VP2. Preliminary murine immunogenicity studies showed that the PB vaccine candidates elicited anti-VP2 immune responses in mice without the use of adjuvant. Conclusions: These proof of concept results demonstrate that Zera®-VP2ep and Zera®-VP2 have potential as BTV vaccines and their development should be further investigated.
dc.identifier.apacitationvan Zyl, A. R., Meyers, A. E., & Rybicki, E. P. (2017). Development of plant-produced protein body vaccine candidates for bluetongue virus. http://hdl.handle.net/11427/24469en_ZA
dc.identifier.chicagocitationvan Zyl, Albertha R, Ann E Meyers, and Edward P Rybicki "Development of plant-produced protein body vaccine candidates for bluetongue virus." (2017) http://hdl.handle.net/11427/24469en_ZA
dc.identifier.citationvan Zyl, A. R., Meyers, A. E., & Rybicki, E. P. (2017). Development of plant-produced protein body vaccine candidates for bluetongue virus. BMC Biotechnology, 17(1), 47.
dc.identifier.ris TY - Journal Article AU - van Zyl, Albertha R AU - Meyers, Ann E AU - Rybicki, Edward P AB - Background: Bluetongue is a disease of domestic and wild ruminants caused by bluetongue virus serotypes (BTV), which have caused serious outbreaks worldwide. Commercially available vaccines are live-attenuated or inactivated virus strains: these are effective, but there is the risk of reversion to virulence or reassortment with circulating strains for live virus, and residual live virus for the inactivated vaccines. The live-attenuated virus vaccines are not able to distinguish naturally infected animals from vaccinated animals (DIVA compliant). Recombinant vaccines are preferable to minimize the risks associated with these vaccines, and would also enable the development of candidate vaccines that are DIVA-compliant. Results: In this study, two novel protein body (PB) plant-produced vaccines were developed, Zera®-VP2ep and Zera®-VP2. Zera®-VP2ep contained B-cell epitope sequences of multiple BTV serotypes and Zera®-VP2 contained the full-length BTV-8 VP2 codon-optimised sequence. In addition to fulfilling the DIVA requirement, Zera®-VP2ep was aimed at being multivalent with the ability to stimulate an immune response to several BTV serotypes. Both these candidate vaccines were successfully made in N. benthamiana via transient Agrobacterium-mediated expression, and in situ TEM analysis showed that the expressed proteins accumulated within the cytoplasm of plant cells in dense membrane-defined PBs. The peptide sequences included in Zera®-VP2ep contained epitopes that bound antibodies produced against native VP2. Preliminary murine immunogenicity studies showed that the PB vaccine candidates elicited anti-VP2 immune responses in mice without the use of adjuvant. Conclusions: These proof of concept results demonstrate that Zera®-VP2ep and Zera®-VP2 have potential as BTV vaccines and their development should be further investigated. DA - 2017-05-30 DB - OpenUCT DO - 10.1186/s12896-017-0370-5 DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2017 T1 - Development of plant-produced protein body vaccine candidates for bluetongue virus TI - Development of plant-produced protein body vaccine candidates for bluetongue virus UR - http://hdl.handle.net/11427/24469 ER - en_ZA
dc.identifier.urihttp://dx.doi.org/10.1186/s12896-017-0370-5
dc.identifier.urihttp://hdl.handle.net/11427/24469
dc.identifier.vancouvercitationvan Zyl AR, Meyers AE, Rybicki EP. Development of plant-produced protein body vaccine candidates for bluetongue virus. 2017; http://hdl.handle.net/11427/24469.en_ZA
dc.language.isoen
dc.publisherBioMed Central
dc.publisher.departmentDepartment of Molecular and Cell Biologyen_ZA
dc.publisher.facultyFaculty of Scienceen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rights.holderThe Author(s).
dc.subject.otherBluetongue virus
dc.subject.otherProtein body
dc.subject.otherNicotiana benthamiana
dc.subject.otherVaccine
dc.subject.otherZera®
dc.titleDevelopment of plant-produced protein body vaccine candidates for bluetongue virus
dc.typeJournal Article
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vanZyl_Article_2017.pdf
Size:
5.36 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles